Company Profile
Entrada Therapeutics Stock Price, News & Catalysts
- Ticker:
- TRDA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.57 USD (-0.39%)
Close
Last updated: August 21, 2026
258M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, TRDA closed down 0.39% at $7.57. No new same-company headline was identified in the current news window.
Company overview
Intracellular Genetic Medicines
Entrada Therapeutics develops Endosomal Escape Vehicle therapeutics intended to deliver oligonucleotides into cells and engage previously inaccessible intracellular targets.
ENTR-601-44
ENTR-601-44 is an exon-skipping candidate for people with Duchenne muscular dystrophy amenable to exon 44 skipping.
ENTR-601-45
ENTR-601-45 applies the same intracellular-delivery platform to patients amenable to exon 45 skipping.
ELEVATE Clinical Program
The ELEVATE studies evaluate multiple ascending doses, safety, target engagement and early functional outcomes to guide further development of Entrada's Duchenne franchise.
Future catalysts
- ELEVATE-45-201 Cohort 1 data around mid-2026.
- ELEVATE-44-201 open-label-period and Cohort 2 data by year-end 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Entrada Therapeutics (TRDA)?
Entrada Therapeutics (TRDA) most recently closed at 7.57 USD, a -0.39% move versus the previous session.
What is the market cap of Entrada Therapeutics (TRDA)?
Entrada Therapeutics currently has a market capitalization of 258M USD on BioPharmSignal.
What does Entrada Therapeutics do?
Intracellular Genetic Medicines Entrada Therapeutics develops Endosomal Escape Vehicle therapeutics intended to deliver oligonucleotides into cells and engage previously inaccessible intracellular targets. ENTR-601-44 ENTR-601-44 is an exon-skipping candidate for people with Duchenne muscular dystrophy amenable to exon 44 skipping. ENTR-601-45 ENTR-601-45...
On which exchange is TRDA stock listed?
Entrada Therapeutics (TRDA) is associated with NASDAQ, United States, Biopharma.
What is ENTR-601-44?
ENTR-601-44 ENTR-601-44 is an exon-skipping candidate for people with Duchenne muscular dystrophy amenable to exon 44 skipping.
Which conditions is Entrada Therapeutics targeting with ENTR-601-44?
Entrada Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.
How does Entrada Therapeutics describe recent progress with ENTR-601-44?
ELEVATE-45-201 Cohort 1 data around mid-2026. ELEVATE-44-201 open-label-period and Cohort 2 data by year-end 2026.
What is ENTR-601-45?
ENTR-601-45 ENTR-601-45 applies the same intracellular-delivery platform to patients amenable to exon 45 skipping.